You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiazepam
Accession NumberDB00829  (APRD00642, DB07699)
TypeSmall Molecule
GroupsApproved, Illicit, Vet Approved
DescriptionA benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589)
Structure
Thumb
Synonyms
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Diazepam
Methyl diazepinone
Valium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-diazepamtablet10 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-diazepamtablet2 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-diazepamtablet5 mgoralBiomed Pharma2003-04-23Not applicableCanada
Diastatgel20 mg/4mLrectalValeant Pharmaceuticals North America LLC1997-07-29Not applicableUs
Diastatgel2.5 mg/.5mLrectalValeant Pharmaceuticals North America LLC1997-07-29Not applicableUs
Diastatgel10 mg/2mLrectalValeant Pharmaceuticals North America LLC1997-07-29Not applicableUs
Diastatgel5 mgrectalValeant Pharmaceuticals North America LLC2000-01-28Not applicableCanada
Diazemulsemulsion5 mgintramuscular; intravenousActavis Group Ptc Ehf1995-12-312016-01-05Canada
Diazepamgel2.5 mg/.5mLrectalTeva Pharmaceuticals USA Inc2010-10-01Not applicableUs
Diazepamgel10 mg/2mLrectalTeva Pharmaceuticals USA Inc2010-09-03Not applicableUs
Diazepamgel20 mg/4mLrectalTeva Pharmaceuticals USA Inc2010-09-03Not applicableUs
Diazepam 10mg Tabletstablet10 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Diazepam 10tab 10mgtablet10 mgoralPro Doc Limitee1978-12-31Not applicableCanada
Diazepam 2mg Tabletstablet2 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Diazepam 2tab 2mgtablet2 mgoralPro Doc Limitee1978-12-312012-07-23Canada
Diazepam 5 Tabtablet5 mgoralPro Doc Limitee1974-12-31Not applicableCanada
Diazepam 5mg Tabletstablet5 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Diazepam Autoinjectorliquid5 mgintramuscularMeridian Medical Technologies Inc.2007-01-24Not applicableCanada
Diazepam Injection Sdzsolution5 mgintramuscular; intravenousSandoz Canada Incorporated2013-03-27Not applicableCanada
Diazepam Injection USPsolution5 mgintramuscular; intravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Diazepam Injection USPsolution5 mgintramuscular; intravenousSandoz Canada Incorporated1980-12-31Not applicableCanada
E Pam Tab 10mgtablet10 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
E Pam Tab 2mgtablet2 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
E Pam Tab 5mgtablet5 mgoralIcn Canada Ltd.1973-12-312005-04-26Canada
Meval 2tablet2 mgoralMedic Laboratory LtÉe1973-12-311996-09-09Canada
Meval 5tablet5 mgoralMedic Laboratory LtÉe1973-12-311996-09-09Canada
Novo-dipam Tab 10mgtablet10 mgoralNovopharm Limited1973-12-312015-10-26Canada
Novo-dipam Tab 2mgtablet2 mgoralNovopharm Limited1973-12-312015-10-26Canada
Novo-dipam Tab 5mgtablet5 mgoralNovopharm Limited1973-12-312015-10-26Canada
PMS-diazepamtablet2 mgoralPharmascience Inc2003-12-10Not applicableCanada
PMS-diazepamtablet5 mgoralPharmascience Inc2003-12-10Not applicableCanada
PMS-diazepamtablet10 mgoralPharmascience Inc2003-12-10Not applicableCanada
PMS-diazepam Solution 1mg/mlsolution1 mgoralPharmascience Inc1992-12-31Not applicableCanada
Valiumtablet5 mg/1oralPd Rx Pharmaceuticals, Inc.1963-11-15Not applicableUs
Valiumtablet5 mg/1oralGenentech, Inc.1963-11-15Not applicableUs
Valiumtablet5 mg/1oralREMEDYREPACK INC.2012-11-28Not applicableUs
Valiumtablet10 mg/1oralGenentech, Inc.1963-11-15Not applicableUs
Valiumtablet5 mg/1oralCardinal Health1963-11-15Not applicableUs
Valiumtablet10 mg/1oralCardinal Health1963-11-15Not applicableUs
Valiumtablet2 mg/1oralGenentech, Inc.1963-11-15Not applicableUs
Valium 10 Tabtablet10 mgoralHoffmann La Roche Limited1978-12-312001-07-19Canada
Valium 5 Tabtablet5 mgoralHoffmann La Roche Limited1978-12-31Not applicableCanada
Valium Inj Roche 5mg/mlliquid10 mgintramuscular; intravenousHoffmann La Roche Limited1968-12-312000-07-27Canada
Vivoltablet10 mgAxxess Pharma Inc.1970-12-312011-07-22Canada
Vivoltablet2 mgoralCarter Horner Corp.1970-12-312004-07-09Canada
Vivoltablet5 mgAxxess Pharma Inc.1970-12-312011-07-22Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Diazepam Tab 10mgtablet10 mgoralApotex Inc1979-12-31Not applicableCanada
Apo Diazepam Tab 2mgtablet2 mgoralApotex Inc1979-12-31Not applicableCanada
Apo Diazepam Tab 5mgtablet5 mgoralApotex Inc1977-12-31Not applicableCanada
Diazepaminjection, solution5 mg/mLintramuscularREMEDYREPACK INC.2016-03-07Not applicableUs
Diazepamtablet5 mg/1oralDIRECT RX2015-01-01Not applicableUs
Diazepamtablet2 mg/1oralMylan Institutional Inc.1997-10-31Not applicableUs
Diazepamtablet10 mg/1oralContract Pharmacy Services Pa2011-03-29Not applicableUs
Diazepamtablet10 mg/1oralKAISER FOUNDATION HOSPITALS2002-01-29Not applicableUs
Diazepamtablet5 mg/1oralApotheca, Inc.2009-12-09Not applicableUs
Diazepamtablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralCardinal Health2009-10-13Not applicableUs
Diazepamtablet5 mg/1oralMc Kesson Contract Packaging2011-10-13Not applicableUs
Diazepamtablet5 mg/1oralPd Rx Pharmaceuticals, Inc.1987-02-03Not applicableUs
Diazepamtablet10 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet2 mg/1oralTYA Pharmaceuticals1986-12-10Not applicableUs
Diazepamtablet10 mg/1oralActavis Pharma, Inc.1987-02-03Not applicableUs
Diazepamtablet10 mg/1oralRebel Distributors Corp.2009-11-09Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousA S Medication Solutions Llc1987-10-13Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.1988-12-20Not applicableUs
Diazepamtablet10 mg/1oralSTAT Rx USA LLC2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralAphena Pharma Solutions Tennessee, Llc2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralCardinal Health2009-11-09Not applicableUs
Diazepamtablet10 mg/1oralbryant ranch prepack2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralPreferred Pharmaceuticals, Inc.2011-11-09Not applicableUs
Diazepamtablet5 mg/1oralIVAX Pharmaceuticals, Inc.1986-12-10Not applicableUs
Diazepamtablet10 mg/1oralQualitest Pharmaceuticals2006-03-31Not applicableUs
Diazepamtablet2 mg/1oralAidarex Pharmaceuticals LLC2006-03-31Not applicableUs
Diazepamtablet2 mg/1oralPhysicians Total Care, Inc.2008-07-23Not applicableUs
Diazepamtablet2 mg/1oralREMEDYREPACK INC.2015-07-22Not applicableUs
Diazepamtablet5 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralDispensing Solutions, Inc.2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralCardinal Health2009-11-20Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousGENERAL INJECTABLES AND VACCINES, INC.2010-05-01Not applicableUs
Diazepamtablet5 mg/1oralProficient Rx LP1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralMylan Institutional Inc.1997-11-04Not applicableUs
Diazepamtablet5 mg/1oralRed Pharm Drug Inc.2006-05-01Not applicableUs
Diazepamtablet2 mg/1oralMylan Pharmaceuticals Inc.1985-09-04Not applicableUs
Diazepamtablet10 mg/1oralApotheca, Inc.2009-01-15Not applicableUs
Diazepamtablet10 mg/1oralSTAT Rx USA LLC2009-11-20Not applicableUs
Diazepamtablet5 mg/1oralPhysicians Total Care, Inc.2008-08-19Not applicableUs
Diazepamtablet10 mg/1oralMc Kesson Contract Packaging2009-11-09Not applicableUs
Diazepamtablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2009-11-20Not applicableUs
Diazepamtablet2 mg/1oralA S Medication Solutions Llc1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralTYA Pharmaceuticals1986-12-10Not applicableUs
Diazepamsolution5 mg/5mLoralRoxane Laboratories, Inc1987-04-03Not applicableUs
Diazepamtablet2 mg/1oralActavis Pharma, Inc.1987-02-03Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousRebel Distributors Corp1987-10-13Not applicableUs
Diazepamtablet2 mg/1oralA S Medication Solutions Llc1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralPreferred Pharmaceuticals, Inc.2011-11-09Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.1987-10-13Not applicableUs
Diazepamsolution5 mg/5mLoralAtlantic Biologicals Corps1987-04-03Not applicableUs
Diazepamtablet2 mg/1oralAphena Pharma Solutions Tennessee, Llc2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralCardinal Health2009-11-09Not applicableUs
Diazepamtablet2 mg/1oralbryant ranch prepack1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Diazepamtablet5 mg/1oralUnit Dose Services1986-12-10Not applicableUs
Diazepamtablet2 mg/1oralDispensing Solutions, Inc.1987-02-03Not applicableUs
Diazepamtablet10 mg/1oralIVAX Pharmaceuticals, Inc.1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralMajor Pharmaceuticals2008-06-05Not applicableUs
Diazepamtablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-02-03Not applicableUs
Diazepamtablet5 mg/1oralCardinal Health2006-11-15Not applicableUs
Diazepamtablet5 mg/1oralSTAT Rx USA LLC2009-11-20Not applicableUs
Diazepamtablet5 mg/1oralCardinal Health2009-11-20Not applicableUs
Diazepaminjection5 mg/mLintramuscular; intravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs
Diazepamtablet10 mg/1oralProficient Rx LP1986-12-10Not applicableUs
Diazepamtablet10 mg/1oralMylan Institutional Inc.1997-10-31Not applicableUs
Diazepamtablet10 mg/1oralAphena Pharma Solutions Tennessee, Llc2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralMylan Pharmaceuticals Inc.1985-09-04Not applicableUs
Diazepamtablet2 mg/1oralSTAT Rx USA LLC2006-03-31Not applicableUs
Diazepamtablet2 mg/1oralQualitest Pharmaceuticals2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralAidarex Pharmaceuticals LLC2006-03-31Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2002-02-13Not applicableUs
Diazepamtablet5 mg/1oralAmerican Health Packaging2009-10-132015-12-29Us
Diazepamtablet2 mg/1oralPd Rx Pharmaceuticals, Inc.1987-02-03Not applicableUs
Diazepamtablet2 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralTYA Pharmaceuticals1987-02-03Not applicableUs
Diazepamsolution5 mg/5mLoralRoxane Laboratories, Inc1990-06-14Not applicableUs
Diazepamtablet10 mg/1oralbryant ranch prepack2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Diazepamsolution, concentrate5 mg/mLoralLannett Company, Inc.2014-04-14Not applicableUs
Diazepamtablet2 mg/1oralRebel Distributors Corp.2009-11-09Not applicableUs
Diazepamtablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousCardinal Health1988-12-20Not applicableUs
Diazepamtablet2 mg/1oralAvera Mc Kennan Hospital2015-05-05Not applicableUs
Diazepamtablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Diazepamtablet10 mg/1oralUnit Dose Services2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralContract Pharmacy Services Pa2011-08-01Not applicableUs
Diazepamtablet5 mg/1oralKAISER FOUNDATION HOSPITALS2002-01-29Not applicableUs
Diazepamtablet10 mg/1oralBlenheim Pharmacal, Inc.2010-04-13Not applicableUs
Diazepamtablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-02-03Not applicableUs
Diazepamsolution5 mg/5mLoralCardinal Health2012-02-22Not applicableUs
Diazepamtablet10 mg/1oralMylan Pharmaceuticals Inc.1985-09-04Not applicableUs
Diazepamtablet5 mg/1oralSTAT Rx USA LLC2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralPd Rx Pharmaceuticals, Inc.1987-02-03Not applicableUs
Diazepamtablet2 mg/1oralCardinal Health2009-11-20Not applicableUs
Diazepamtablet5 mg/1oralbryant ranch prepack1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralREMEDYREPACK INC.2013-07-03Not applicableUs
Diazepamsolution5 mg/5mLoralPrecision Dose Inc.2012-02-22Not applicableUs
Diazepamtablet2 mg/1oralIVAX Pharmaceuticals, Inc.1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralQualitest Pharmaceuticals2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralAidarex Pharmaceuticals LLC2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralPhysicians Total Care, Inc.2004-06-03Not applicableUs
Diazepamtablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC1986-12-10Not applicableUs
Diazepamtablet5 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet10 mg/1oralDispensing Solutions, Inc.2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2006-11-15Not applicableUs
Diazepamtablet10 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepamtablet5 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Diazepamtablet5 mg/1oralActavis Pharma, Inc.1987-02-03Not applicableUs
Diazepamtablet5 mg/1oralRebel Distributors Corp.2009-11-09Not applicableUs
Diazepamtablet10 mg/1oralA S Medication Solutions Llc2006-03-31Not applicableUs
Diazepaminjection, solution5 mg/mLintramuscular; intravenousCardinal Health1987-10-13Not applicableUs
Diazepam Intensolsolution, concentrate5 mg/mLoralRoxane Laboratories, Inc1987-04-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiapamOrion
NerviumSaba
RelaniumGlaxoSmithKline
Brand mixtures
NameLabellerIngredients
Gabavale-5Physician Therapeutics Llc
SaltsNot Available
Categories
UNIIQ3JTX2Q7TU
CAS number439-14-5
WeightAverage: 284.74
Monoisotopic: 284.071640755
Chemical FormulaC16H13ClN2O
InChI KeyInChIKey=AAOVKJBEBIDNHE-UHFFFAOYSA-N
InChI
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
IUPAC Name
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.
PharmacodynamicsDiazepam, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors which mediate sleep, affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionEssentially complete, with a bioavailability of 93%.
Volume of distribution
  • 0.8 to 1.0 L/kg [young healthy males]
Protein binding98.5%
Metabolism

Hepatic via the Cytochrome P450 enzyme system. The main active metabolite is desmethyldiazepam, in addition to minor active metabolites including temazepam and oxazepam.

SubstrateEnzymesProduct
Diazepam
NordiazepamDetails
Diazepam
TemazepamDetails
Diazepam
OxazepamDetails
Diazepam
Not Available
desmethyldiazepamDetails
Nordiazepam
OxazepamDetails
Temazepam
OxazepamDetails
Nordiazepam
Not Available
Nordiazepam O-glucuronideDetails
Route of eliminationDiazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates.
Half lifeBiphasic 1-2 days and 2-5 days, active metabolites with long half lives.
Clearance
  • 20-30 mL/min
ToxicitySymptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9934
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.661
P-glycoprotein inhibitor INon-inhibitor0.5557
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.6152
CYP450 2C9 substrateNon-substrate0.6699
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.8177
CYP450 1A2 substrateInhibitor0.8175
CYP450 2C9 inhibitorNon-inhibitor0.5562
CYP450 2D6 inhibitorNon-inhibitor0.858
CYP450 2C19 inhibitorInhibitor0.5221
CYP450 3A4 inhibitorInhibitor0.6423
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5693
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8312
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5946 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9948
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Roxane laboratories inc
  • Valeant pharmaceuticals international
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Parenta pharmaceuticals inc
  • Us army medical research materiel command
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Pharmacia and upjohn co
  • Actavis elizabeth llc
  • Barr laboratories inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ferndale laboratories inc
  • Halsey drug co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Martec usa llc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Quantum pharmics ltd
Packagers
Dosage forms
FormRouteStrength
Tabletoral2 mg
Gelrectal5 mg
Emulsionintramuscular; intravenous5 mg
Gelrectal10 mg/2mL
Gelrectal2.5 mg/.5mL
Gelrectal20 mg/4mL
Injectionintramuscular; intravenous5 mg/mL
Injection, solutionintramuscular5 mg/mL
Injection, solutionintramuscular; intravenous5 mg/mL
Solutionoral5 mg/5mL
Tabletoral10 mg
Tabletoral5 mg
Liquidintramuscular5 mg
Solutionintramuscular; intravenous5 mg
Solution, concentrateoral5 mg/mL
Kit
Solutionoral1 mg
Tabletoral10 mg/1
Tabletoral2 mg/1
Tabletoral5 mg/1
Liquidintramuscular; intravenous10 mg
Tablet10 mg
Tablet5 mg
Prices
Unit descriptionCostUnit
Diastat acudial 12.5-15-20 mg429.58USD each
Diastat acudial 5-7.5-10 mg kit429.58USD kit
Diastat AcuDial 10 mg Gel 1 Box Contains Two 10 mg Syringes423.95USD box
Diastat AcuDial 20 mg Gel 1 Box Contains Two 20 mg Syringes413.6USD box
Diastat 2.5 mg pedi system362.12USD each
Valium 10 mg tablet6.06USD tablet
Diazepam powder3.99USD g
Valium 5 mg tablet2.55USD tablet
Valium 2 mg tablet2.43USD tablet
Diazemuls 5 mg/ml Emulsion1.23USD ml
Diazepam 5 mg/ml0.69USD ml
Diazepam 10 mg tablet0.38USD tablet
Diazepam 5 mg tablet0.3USD tablet
Diazepam 2 mg tablet0.26USD tablet
Diazepam 5 mg/ml vial0.17USD ml
Apo-Diazepam 10 mg Tablet0.09USD tablet
Apo-Diazepam 5 mg Tablet0.07USD tablet
Apo-Diazepam 2 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2171627 No2006-01-312014-09-12Canada
US5462740 No1993-09-172013-09-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point125-126Chase, G.; U.S. Patent 3,102,116; August 27, 1963; assigned to Hoffmann-La Roche Inc. Reeder, E. and Sternbach, L.H.; U.S. Patent 3,109,843; November 5, 1963; assigned to Hoffmann-La Roche lnc. Reeder, E. and Sternbach, L.H.; U.S. Patent 3,136,815; June 9, 1964; assigned to Hoffmann- La Roche Inc. Reeder, E. and Sternbach, L.H.; US. Patent 3,371,085; February 27, 1968; assigned to Hoffmann-La Roche Inc.
water solubility50 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.82SANGSTER (1994)
Caco2 permeability-4.32ADME Research, USCD
pKa3.4MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP2.63ALOGPS
logP3.08ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)2.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity79.81 m3·mol-1ChemAxon
Polarizability29.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.4 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a59-2490000000-41352db33c43d0b96876View in MoNA
References
Synthesis Reference

Chase, G.; U.S. Patent 3,102,116; August 27, 1963; assigned to Hoffmann-La Roche Inc. Reeder, E. and Sternbach, L.H.; U.S. Patent 3,109,843; November 5, 1963; assigned to
Hoffmann-La Roche lnc.
Reeder, E. and Sternbach, L.H.; U.S. Patent 3,136,815; June 9, 1964; assigned to Hoffmann-
La Roche Inc.
Reeder, E. and Sternbach, L.H.; US. Patent 3,371,085; February 27, 1968; assigned to
Hoffmann-La Roche Inc.

General References
  1. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D: Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health. 1993 Dec;17(4):345-9. [PubMed:7911332 ]
  2. Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [PubMed:458601 ]
  3. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. [PubMed:11995921 ]
  4. Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. [PubMed:3089825 ]
  5. McLean MJ, Macdonald RL: Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther. 1988 Feb;244(2):789-95. [PubMed:2450203 ]
External Links
ATC CodesN05BA01
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelDownload (260 KB)
MSDSDownload (53.1 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Diazepam is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Diazepam can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Aceprometazine.
AcetaminophenThe serum concentration of Diazepam can be increased when it is combined with Acetaminophen.
adipiplonThe risk or severity of adverse effects can be increased when Diazepam is combined with adipiplon.
AfatinibThe serum concentration of Diazepam can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Diazepam is combined with Agomelatine.
AlbendazoleThe serum concentration of Diazepam can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Diazepam can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Diazepam can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Diazepam is combined with Alfaxalone.
AlfentanilDiazepam may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlfentanilThe serum concentration of Diazepam can be increased when it is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Diazepam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diazepam.
AmantadineThe serum concentration of Diazepam can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Diazepam can be increased when it is combined with Aminohippuric acid.
AminophyllineThe therapeutic efficacy of Diazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe serum concentration of Diazepam can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Diazepam is combined with Amisulpride.
AmitriptylineThe serum concentration of Diazepam can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Diazepam is combined with Amitriptyline.
AmlodipineThe serum concentration of Diazepam can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Diazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Diazepam is combined with Amperozide.
AmprenavirThe serum concentration of Diazepam can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Diazepam can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Diazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Diazepam is combined with Aripiprazole.
ArmodafinilThe metabolism of Diazepam can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Diazepam is combined with Asenapine.
AstemizoleThe serum concentration of Diazepam can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Diazepam can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Diazepam can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Diazepam can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Diazepam can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Azaperone.
AzelastineDiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Diazepam can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Diazepam can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Diazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Barbital.
BenzocaineThe serum concentration of Diazepam can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Diazepam is combined with Benzyl alcohol.
BepridilThe serum concentration of Diazepam can be increased when it is combined with Bepridil.
BexaroteneThe serum concentration of Diazepam can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Diazepam can be increased when it is combined with Biperiden.
BoceprevirThe metabolism of Diazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Diazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Diazepam can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Diazepam can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Diazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Bromazepam.
BromocriptineThe serum concentration of Diazepam can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Diazepam.
BuprenorphineThe serum concentration of Diazepam can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Buprenorphine.
BuspironeThe serum concentration of Diazepam can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Diazepam is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diazepam.
ButacaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Diazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Diazepam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diazepam.
CabazitaxelThe serum concentration of Diazepam can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Diazepam can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Diazepam can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Diazepam can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Diazepam can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Diazepam can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Diazepam can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Diazepam is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Diazepam is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Diazepam is combined with Carisoprodol.
CarvedilolThe serum concentration of Diazepam can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Diazepam can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Diazepam can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Diazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Diazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Diazepam is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Diazepam can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Chloroprocaine.
ChloroquineThe serum concentration of Diazepam can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Diazepam can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Diazepam can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Diazepam can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Diazepam can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Diazepam can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Diazepam can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Diazepam can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Diazepam.
CimetidineThe serum concentration of Diazepam can be decreased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diazepam.
CiprofloxacinThe serum concentration of Diazepam can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Diazepam is combined with Citalopram.
CitalopramThe serum concentration of Diazepam can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Diazepam can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Diazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Diazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Diazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clobazam.
ClofazimineThe serum concentration of Diazepam can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Diazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Clomipramine.
ClomipramineThe serum concentration of Diazepam can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonidine.
ClopidogrelThe metabolism of Diazepam can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diazepam.
ClotrimazoleThe metabolism of Diazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Diazepam.
CobicistatThe serum concentration of Diazepam can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Diazepam.
ColchicineThe serum concentration of Diazepam can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Diazepam can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Diazepam can be increased when it is combined with Conivaptan.
CosyntropinCosyntropin may increase the hepatotoxic activities of Diazepam.
CrizotinibThe metabolism of Diazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Diazepam can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Diazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Diazepam can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Diazepam can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Diazepam can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Diazepam can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Diazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dapoxetine.
DarunavirThe metabolism of Diazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Diazepam can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Diazepam can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Diazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Diazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Diazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Diazepam is combined with Desflurane.
DesipramineThe serum concentration of Diazepam can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Desipramine.
DesloratadineThe serum concentration of Diazepam can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Diazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Diazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diazepam.
DextromethorphanThe serum concentration of Diazepam can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Diazepam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diazepam.
DezocineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dezocine.
DiclofenacThe serum concentration of Diazepam can be increased when it is combined with Diclofenac.
DifenoxinThe risk or severity of adverse effects can be increased when Diazepam is combined with Difenoxin.
DigoxinThe serum concentration of Diazepam can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Diazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydromorphine.
DiltiazemThe metabolism of Diazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Diazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diazepam is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Diazepam can be increased when it is combined with Dipyridamole.
DisulfiramThe serum concentration of Diazepam can be increased when it is combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Diazepam is combined with Doramectin.
DoxazosinThe serum concentration of Diazepam can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Diazepam can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Diazepam is combined with Doxepin.
DoxorubicinThe serum concentration of Diazepam can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Diazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Diazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DronedaroneThe metabolism of Diazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Diazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Diazepam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diazepam.
DyphyllineThe therapeutic efficacy of Diazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Diazepam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Diazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Diazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Diazepam is combined with Efavirenz.
ElbasvirThe serum concentration of Diazepam can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Diazepam can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Diazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Diazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Diazepam can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Diazepam can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Diazepam can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Diazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Diazepam can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Diazepam can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Estazolam.
EstramustineThe serum concentration of Diazepam can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Diazepam can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Diazepam can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diazepam.
EthanolDiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Diazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Diazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Diazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Diazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Etoperidone.
EtoposideThe serum concentration of Diazepam can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Etorphine.
EtravirineThe serum concentration of Diazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Diazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Diazepam is combined with Felbamate.
FelodipineThe serum concentration of Diazepam can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fenfluramine.
FentanylThe serum concentration of Diazepam can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Diazepam is combined with Fentanyl.
FexofenadineThe serum concentration of Diazepam can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fexofenadine.
FidaxomicinThe serum concentration of Diazepam can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Diazepam is combined with Flibanserin.
FloxuridineThe metabolism of Diazepam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Diazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Diazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flunitrazepam.
FluorouracilThe metabolism of Diazepam can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluoxetine.
FluoxetineThe serum concentration of Diazepam can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Diazepam can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Diazepam is combined with Flupentixol.
FluphenazineThe serum concentration of Diazepam can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluphenazine.
FlurazepamThe serum concentration of Diazepam can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Diazepam can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Diazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Diazepam can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Diazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Diazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Diazepam.
FospropofolThe risk or severity of adverse effects can be increased when Diazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Diazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Diazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Diazepam is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Diazepam can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Diazepam can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Diazepam can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Diazepam is combined with Glutethimide.
GlyburideThe serum concentration of Diazepam can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Diazepam can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Diazepam can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Diazepam can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Diazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Diazepam.
HaloperidolThe serum concentration of Diazepam can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Diazepam is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Diazepam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Diazepam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Diazepam can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Diazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Diazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Iloperidone.
ImatinibThe metabolism of Diazepam can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Diazepam can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Diazepam is combined with Indalpine.
IndinavirThe serum concentration of Diazepam can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Diazepam can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Diazepam can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Diazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Diazepam.
IsoniazidThe metabolism of Diazepam can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Diazepam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Diazepam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Diazepam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Diazepam can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Diazepam can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketobemidone.
KetoconazoleThe serum concentration of Diazepam can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Diazepam is combined with Lamotrigine.
LansoprazoleThe serum concentration of Diazepam can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Diazepam can be increased when it is combined with Lapatinib.
LeflunomideThe metabolism of Diazepam can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Diazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Diazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Diazepam is combined with Levodopa.
LevofloxacinThe serum concentration of Diazepam can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Diazepam is combined with Levorphanol.
LevothyroxineThe serum concentration of Diazepam can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Diazepam can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Lidocaine.
LiothyronineThe serum concentration of Diazepam can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Diazepam can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Diazepam can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Diazepam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Diazepam is combined with Lofentanil.
LomitapideThe serum concentration of Diazepam can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Diazepam can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Diazepam can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Diazepam can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Diazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diazepam.
LosartanThe serum concentration of Diazepam can be increased when it is combined with Losartan.
LovastatinThe metabolism of Diazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Diazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Diazepam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Diazepam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Diazepam is combined with Magnesium Sulfate.
MaprotilineThe serum concentration of Diazepam can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Diazepam is combined with Maprotiline.
MebendazoleThe serum concentration of Diazepam can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Diazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Medetomidine.
MefloquineThe serum concentration of Diazepam can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Diazepam can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Diazepam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Mepivacaine.
MeprobamateThe serum concentration of Diazepam can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Diazepam is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Diazepam is combined with Metaxalone.
MethadoneDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe serum concentration of Diazepam can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Diazepam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Diazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Diazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Diazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Diazepam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Methylphenobarbital.
MetoprololThe serum concentration of Diazepam can be increased when it is combined with Metoprolol.
MetyrosineDiazepam may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Diazepam can be decreased when combined with Mexiletine.
MianserinThe therapeutic efficacy of Diazepam can be decreased when used in combination with Mianserin.
MibefradilThe serum concentration of Diazepam can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Diazepam can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Diazepam can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Midazolam.
MifepristoneThe metabolism of Diazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Diazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
MirtazapineDiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Diazepam.
MitomycinThe serum concentration of Diazepam can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Diazepam can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Diazepam can be decreased when it is combined with Mitoxantrone.
MoclobemideThe metabolism of Diazepam can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Diazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Molindone.
MorphineThe serum concentration of Diazepam can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
NabiloneThe risk or severity of adverse effects can be increased when Diazepam is combined with Nabilone.
NafcillinThe serum concentration of Diazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Diazepam is combined with Nalbuphine.
NaltrexoneThe serum concentration of Diazepam can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Diazepam can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Diazepam can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Diazepam can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Diazepam can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Diazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Diazepam can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Diazepam can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Diazepam can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Diazepam can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Diazepam.
NisoldipineThe serum concentration of Diazepam can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Diazepam can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nitrazepam.
NitrendipineThe serum concentration of Diazepam can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Diazepam is combined with Nitrous oxide.
NorethisteroneThe serum concentration of Diazepam can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Diazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diazepam.
OlaparibThe metabolism of Diazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Diazepam is combined with Olopatadine.
OmeprazoleThe serum concentration of Diazepam can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Diazepam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Diazepam is combined with Opium.
OrlistatThe serum concentration of Diazepam can be decreased when it is combined with Orlistat.
OrphenadrineDiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Diazepam.
OsanetantThe risk or severity of adverse effects can be increased when Diazepam is combined with Osanetant.
OsimertinibThe serum concentration of Diazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Diazepam can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Diazepam can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Diazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.
Palmitic AcidThe serum concentration of Diazepam can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Diazepam can be increased when it is combined with Pantoprazole.
ParaldehydeDiazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Diazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Diazepam is combined with Paroxetine.
ParoxetineThe serum concentration of Diazepam can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diazepam.
PerampanelThe risk or severity of adverse effects can be increased when Diazepam is combined with Perampanel.
PerindoprilThe serum concentration of Diazepam can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Diazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Diazepam.
PhenobarbitalThe serum concentration of Diazepam can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Diazepam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Diazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Diazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Diazepam.
PimozideThe serum concentration of Diazepam can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Diazepam is combined with Pimozide.
PioglitazoneThe metabolism of Diazepam can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Diazepam is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Diazepam can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.
PonatinibThe serum concentration of Diazepam can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Diazepam can be increased when it is combined with Posaconazole.
PramipexoleDiazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Pramocaine.
PravastatinThe serum concentration of Diazepam can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Prazepam.
PrazosinThe serum concentration of Diazepam can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Diazepam can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Diazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Diazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Primidone.
ProbenecidThe serum concentration of Diazepam can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Diazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.
ProgesteroneThe serum concentration of Diazepam can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Diazepam.
PromethazineThe serum concentration of Diazepam can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Promethazine.
PropafenoneThe serum concentration of Diazepam can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Diazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Propoxycaine.
PropranololThe serum concentration of Diazepam can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Diazepam can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Diazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Diazepam is combined with PSD502.
PyrimethamineThe metabolism of Diazepam can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Diazepam can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quazepam.
QuercetinThe serum concentration of Diazepam can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Diazepam is combined with Quetiapine.
QuinacrineThe serum concentration of Diazepam can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Diazepam can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Diazepam can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Diazepam can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Diazepam is combined with Ramelteon.
RanitidineThe serum concentration of Diazepam can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Diazepam can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Diazepam can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Diazepam can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Diazepam is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Diazepam.
ReserpineThe serum concentration of Diazepam can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Diazepam is combined with Reserpine.
RifabutinThe metabolism of Diazepam can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Diazepam can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Diazepam can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Diazepam can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Diazepam.
RitonavirThe serum concentration of Diazepam can be increased when it is combined with Ritonavir.
RolapitantThe serum concentration of Diazepam can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Romifidine.
RopiniroleDiazepam may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Diazepam can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Diazepam.
RosiglitazoneThe metabolism of Diazepam can be decreased when combined with Rosiglitazone.
RotigotineDiazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Diazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Diazepam is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Diazepam can be increased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Diazepam can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diazepam.
SelegilineThe serum concentration of Diazepam can be increased when it is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Diazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Diazepam is combined with Sertraline.
SertralineThe serum concentration of Diazepam can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Diazepam is combined with Sevoflurane.
SildenafilThe metabolism of Diazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Diazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Diazepam can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Diazepam can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Diazepam can be decreased when it is combined with Sirolimus.
Sodium oxybateDiazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Diazepam.
SorafenibThe serum concentration of Diazepam can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Diazepam can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Diazepam can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Diazepam can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Diazepam is combined with Stiripentol.
StreptozocinThe serum concentration of Diazepam can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.
SulfadiazineThe metabolism of Diazepam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Diazepam can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Diazepam can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Diazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Diazepam.
SumatriptanThe serum concentration of Diazepam can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Diazepam can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Diazepam is combined with Suvorexant.
TacrineThe serum concentration of Diazepam can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Diazepam can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Diazepam can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Diazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Diazepam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Diazepam can be increased when it is combined with Taurocholic Acid.
TeduglutideThe serum concentration of Diazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Diazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Diazepam can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Diazepam can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diazepam.
TemsirolimusThe serum concentration of Diazepam can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Diazepam can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Diazepam can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Diazepam can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Diazepam can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Diazepam can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Diazepam can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrodotoxin.
ThalidomideDiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Diazepam.
TheophyllineThe metabolism of Diazepam can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Diazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Diazepam.
ThiotepaThe metabolism of Diazepam can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Diazepam is combined with Tiagabine.
TicagrelorThe serum concentration of Diazepam can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Diazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Diazepam can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Diazepam can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Diazepam is combined with Tolcapone.
TolvaptanThe serum concentration of Diazepam can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Diazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Diazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Diazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Trazodone.
TrazodoneThe serum concentration of Diazepam can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Diazepam is combined with Triazolam.
TrifluoperazineThe serum concentration of Diazepam can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Diazepam can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Triflupromazine.
TrimethoprimThe serum concentration of Diazepam can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Diazepam can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Diazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Triprolidine.
TroleandomycinThe serum concentration of Diazepam can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Diazepam.
ValsartanThe metabolism of Diazepam can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Diazepam can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Diazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Diazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Diazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Vilazodone.
VinblastineThe serum concentration of Diazepam can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Diazepam can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Diazepam can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Diazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Diazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Diazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Diazepam can be decreased when used in combination with Yohimbine.
ZafirlukastThe metabolism of Diazepam can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Diazepam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Diazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Diazepam is combined with Zimelidine.
ZimelidineThe serum concentration of Diazepam can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Diazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Diazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Diazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Diazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Diazepam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Diazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Diazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
potentiator
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G: Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands. Neuropharmacology. 2007 Aug;53(2):318-29. Epub 2007 Jun 2. [PubMed:17631921 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Jung F, Richardson TH, Raucy JL, Johnson EF: Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos. 1997 Feb;25(2):133-9. [PubMed:9029042 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Jung F, Richardson TH, Raucy JL, Johnson EF: Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos. 1997 Feb;25(2):133-9. [PubMed:9029042 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
  2. Brodersen R, Honore B: Drug binding properties of neonatal albumin. Acta Paediatr Scand. 1989 May;78(3):342-6. [PubMed:2545072 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  2. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23